Biography

Guillem is responsible for identifying and evaluating investment opportunities at Ysios Capital.

Guillem has over 10 years of venture capital experience. Prior to joining Ysios, he worked at the Edmond de Rothschild Group in Paris (now Andera Partners). There he was involved in the execution of several investments in Europe and the United States, including successful companies such as Reviral (sold to Pfizer), Axonics Modulation (Nasdaq: AXNX, $3B market cap) and Sanifit (sold to Vifor). Prior to this, he was an analyst at Caixa Capital Risc, where he was part of the life science team.

Guillem is a CFA charterholder. He also holds Bachelor’s degrees in Biotechnology from the Universitat Autonoma de Barcelona, and in Business Administration from the Universitat Pompeu Fabra.

Board positions

Guillem currently serves on the Board of VarmX and Board Observer at Engrail Therapeitics.